Therefore, the differences in IFNγR signaling among different tumor types may be of great significance for modifying and designing CAR-T cells or guiding drug combination therapy by optimizing T-cell-tumor interactions and further improving the efficacy of CAR-T therapy for solid tumors (66). The gene discussed is IFNGR1; the disease is neoplasm.